AKTX (Akari Therapeutics) Total Assets: $33.89 Mil (As of Mar. 2026)

What is Akari Therapeutics Total Assets?

Akari Therapeutics AKTX +7.26% 32 Total Assets is $33.89 Mil as of Mar. 2026. GuruFocus rates AKTX with a GF Score™ of 32/100.

Akari Therapeutics's Total Assets for the quarter that ended in Mar. 2026 was $33.89 Mil.

During the past 12 months, Akari Therapeutics's average Total Assets Growth Rate was -11.00% per year. During the past 3 years, the average Total Assets Growth Rate was 318.60% per year. During the past 5 years, the average Total Assets Growth Rate was 140.90% per year. During the past 10 years, the average Total Assets Growth Rate was 29.50% per year.

During the past 13 years, Akari Therapeutics's highest 3-Year average Total Assets Growth Rate was 318.60%. The lowest was -24.70%. And the median was 43.15%.

Total Assets is connected with ROA %. Akari Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 was -141.40%. Total Assets is also linked to Revenue through Asset Turnover. Akari Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Akari Therapeutics (NAS:AKTX) Total Assets Explanation

Total Assets is connected with ROA %.

Akari Therapeutics's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %	=	Net Income (Q: Mar. 2026 )	/	( (Total Assets (Q: Dec. 2025 )	+	Total Assets (Q: Mar. 2026 ))	/ count )
	=	-57.82	/	( (47.892	+	33.889)	/ 2 )
	=	-57.82	/	40.8905
	=	-141.40 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Akari Therapeutics's Asset Turnover for the quarter that ended in Mar. 2026 is

	Asset Turnover
=	Revenue (Q: Mar. 2026 )	/	( (Total Assets (Q: Dec. 2025 )	+	Total Assets (Q: Mar. 2026 ))	/ count )
=	0	/	( (47.892	+	33.889)	/ 2 )
=	0	/	40.8905
=	0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Akari Therapeutics Total Assets Related Terms

Akari Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Akari Therapeutics's Total Assets can be seen below:

Akari Therapeutics Total Assets Chart

Akari Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Assets

Get a 7-Day Free Trial

11.65

13.83

4.36

50.56

47.89

Akari Therapeutics Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Total Assets	Get a 7-Day Free Trial															50.96	50.91	45.38	47.89	33.89

32GF Score

Akari Therapeutics PLC AKTX

Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Akari Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Akari Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets	=	Total Equity (A: Dec. 2025 )	+	Total Liabilities (A: Dec. 2025 )
	=	28.328	+	19.564
	=	47.89

Akari Therapeutics's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2026 )	+	Total Liabilities (Q: Mar. 2026 )
	=	14.38	+	19.509
	=	33.89

Frequently Asked Questions Learn more about Total Assets →

What does a Total Assets of $33.89 Mil mean?

Akari Therapeutics (AKTX) has a Total Assets of $33.89 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Akari Therapeutics and its competitors.

Is Akari Therapeutics' Total Assets too high?

Akari Therapeutics' current Total Assets is $33.89 Mil. Overall, Akari Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Akari Therapeutics' Total Assets compare to MBRX and JAGX?

Akari Therapeutics' Total Assets of $33.89 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Assets for a Biotechnology company?

A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Assets mean?

A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Akari Therapeutics and its competitors. Akari Therapeutics's current Total Assets is $33.89 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Akari Therapeutics stock overvalued right now?

Akari Therapeutics (AKTX) has a current Total Assets of $33.89 Mil. The current Total Assets is $33.89 Mil. Akari Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Assets calculated?

Total Assets is calculated from a company's financial statements. For Akari Therapeutics (AKTX), the current Total Assets is $33.89 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Akari Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies MBRX JAGX ANEB XCUR BCDA GRTX CELU TVRD HOWL KTTA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 401 East Jackson Street, Suite 3300, Tampa, FL, USA, 33602

Website https://www.akaritx.com

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

32GF Score

Get the complete analysis for AKTX

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.88

Price

View AKTX Analysis

See Total Assets data for all stocks →